← All companies
ARROWHEAD PHARMACEUTICALS, INC.
ARWR - CIK 0000879407
Market cap$9.96 B
Rank#941
SEC filings1,347
ARROWHEAD PHARMACEUTICALS, INC. trades as ARWR and has a market capitalization of $9.96 B, making it the #941 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $829.45M, up 23258.2% from the prior year and net income of -$1.63M. This page tracks ARROWHEAD PHARMACEUTICALS, INC. through 1,347 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$829.45MFY 2025
Net income (latest FY)-$1.63MFY 2025
Operating cash flow (latest FY)$179.55MFY 2025
Total assets (latest FY)$1.39BFY 2025
Net margin-0.2%latest FY
Financial performance
Over the last 9 fiscal years ARROWHEAD PHARMACEUTICALS, INC.'s revenue grew from $158.33K to $829.45M, a compound annual growth rate of 159.0%. Net profit margin expanded from -51614.6% to -0.2% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $9.96 B
- Share price (derived)market cap / shares outstanding
- $70.73
- EPS (diluted)FY 2025
- $-0.01
- Shares outstandingas of 2026-05-01
- 0.14B
- Total equityas of 2026-03-31
- $613.98M
- Return on equity
- -0.3%
- Cash & equivalentsas of 2024-06-30
- $69.40M
- Current ratioas of 2026-03-31
- 6.23
Latest filings
| Filing | Type | Filed |
|---|---|---|
| 144/A | - | 2026-05-19 |
| 144/A | - | 2026-05-19 |
| 144/A | - | 2026-05-19 |
| Insider trade | 4 | 2026-05-14 |
| Insider sale notice | 144 | 2026-05-12 |
| Employee stock plan | S-8 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
Recent press releases
- Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results2026-05-07
“Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value,” said Christopher Anzalone , Ph.D., President and CEO at Arrowhead Pharmaceuticals . “We remain focused on a few key areas as being critical sources of sustainable growth for Arrowhead, and we have made tangible advancements across these areas. These include: strengthening our commercial presence to bring REDEMPLO® and potentially other cardiometabolic products in the future to the many patients and physicians who need it; continuing to deliver best-in-class in discovery, development, and regulatory capabilities in support of a deep pipeline of RNAi therapeutics capable of silencing genes expressed throughout the body to treat various diseases; and, being strategic and disciplined around pipeline, portfolio, and financial
Similar companies
The largest companies sharing ARROWHEAD PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is ARROWHEAD PHARMACEUTICALS, INC.'s market cap?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a market capitalization of $9.96 B as of 2026-06-10, ranking #941 among US-listed companies.
How much revenue does ARROWHEAD PHARMACEUTICALS, INC. make?
ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $829.45M for fiscal year 2025, an increase of 23258.2% year over year.
Is ARROWHEAD PHARMACEUTICALS, INC. profitable?
In its latest fiscal year ARROWHEAD PHARMACEUTICALS, INC. reported a net loss of $1.63M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.